Inflammatory Frailty Index and Mortality after Kidney Transplantation

    loading  Checking for direct PDF access through Ovid



We identified 378 KT recipients at Johns Hopkins Hospital from 2009-2013 who consented to enrollment in a prospective cohort. Fried frailty and inflammatory markers (IL6, TNFalpha, highly sensitive C reactive protein [(HSCRP]) were collected at the time of admission for KT. We evaluated novel inflammatory-frailty indices combining Fried frailty phenotype (comprised of 5 components) plus the addition of individual inflammatory biomarkers (highest tertile of IL6, TNFalpha, HSCRP, or inflammatory index, separately) as a 6th component. Therefore, scores for each novel inflammatory frailty index were 0-6 points, and the presence of ≥3 components was considered frail. We used Kaplan-Meier methods and Cox proportional hazards model to assess mortality risk after KT by inflammatory frailty index. We adjusted Cox models for recipient age, sex, race, Charlson comorbidity index, and donor type.


Five-year survival for patients with and without each novel inflammatory frailty index for frail vs nonfrail was: 81% vs 93% (IL6-frailty), 87% vs 89% (HSCRP-frailty), 83% vs 91% (TNFalpha-frailty), and 83% vs 91% (Inflammatory index-frailty). After adjustment, mortality was 2.04-fold higher for IL6-frail recipients compared to non-IL6-frail (95%CI:1.02-4.10, p=0.05); there were no associations between the mortality and the other inflammatory-frailty indices (HSCRP-frail:1.01,95%CI:0.51-0.98,p=0.9; TNFalpha-frail:1.94,95%CI:0.98-3.83,p=0.06; or inflammatory index-frail:1.66,95%CI:0.84-3.30,p=0.14) recipients. After adjustment, mortality was similar between nonfrail and frail KT recipients measured with Fried frailty (1.63,95%CI:0.75-3.51, p=0.2) and the highest tertile of IL-6 (1.37,95%CI:0.68-2.73, p=0.4).


IL-6 frailty is a unique frailty phenotype, combining biomarkers and physical components that improves upon the Fried frailty phenotype and is more strongly associated with post-KT mortality. Measurement of biomarkers at KT evaluation and transplantation can guide risk assessment and patient counseling.


National Institutes of Health.

Related Topics

    loading  Loading Related Articles